Korean Air seeks to raise 30 bil yen in Samurai bond sale The bond is guaranteed by KEXIM
Translated by Kim So-in 공개 2021-12-13 08:09:05
이 기사는 2021년 12월 13일 08:05 thebell 에 표출된 기사입니다.
Korean Air Lines is preparing to issue a Samurai bond, guaranteed by the Export-Import Bank of Korea (KEXIM), early next year amid ongoing trade conflicts between Korea and Japan.Korean Air has hired a foreign advisory firm to raise 30 billion yen in a Samurai bond issuance next year, with a book building process expected to take place in January 2022.
The company plans to tap the Japanese bond market to refinance existing debt as its 30 billion yen Samurai bond will mature in February 2022.
Korean Air plans to enhance its credit rating by KEXIM’s guarantee. KEXIM provided a guarantee when the airliner sold its maiden three-year Samurai bond in February 2019. It is difficult to raise funds without securing an investment grade in the conservative Japanese market. Back then, Korean Air improved its credit rating, using KEXIM’s credit rating of AA.
The Samurai bond issuance by South Korean companies has been halted since KT Corp sold its Samurai bond in 2019 due to worsening trade conflicts between Korea and Japan.
Market insiders are paying attention whether Korean Air will be able to raise funds through its planned bond sale amid ongoing conflicts between the two countries. Lotte Corp recently sold a three-year Samurai bond worth 8.5 billion yen through a private placement.
Korean Air has tried to raise funds through foreign currency-denominated bonds since last year, which all ended unsuccessfully. (Reporting by Hye-rim Pi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 신세계그룹, '스타필드광주'까지 임영록 사장에게
- 신세계인터, JAJU사업부 확대개편…재도약 본격화
- 락앤락, 적자전환도 꺾지 못한 '주주 반발'
- [Rating Watch]'AA+' 복귀 무산 SK에너지, 계열사 지원 부담 '발목'
- 한양증권, 수익성 개선...부채급증 '문제없다'
- [thebell note]코스닥 상장심사의 '좁은 문'
- 키움증권 엄주성 사장 특명 'IPO 빅딜 잡아라'
- 하나증권, 'IB 체질개선' 가시화…정영균 그룹장 효과
- [IPO 모니터]'흑자 특례' 피앤에스미캐닉스, 100% '신주'
- [부광약품 리바운드 전략]부광의 '10년대계' 콘테라파마, 유럽 파킨슨 임상 실패 '남은 건 미국'